Literature DB >> 18174366

VIP differentially activates beta2 integrins, CR1, and matrix metalloproteinase-9 in human monocytes through cAMP/PKA, EPAC, and PI-3K signaling pathways via VIP receptor type 1 and FPRL1.

Nabil El Zein1, Bassam Badran, Eric Sariban.   

Abstract

The neuropeptide vasoactive intestinal peptide (VIP) regulates the exocytosis of secretory granules in a wide variety of cells of neuronal and non-neuronal origin. In human monocytes, we show that the proinflammatory effects of VIP are associated with stimulation of exocytosis of secretory vesicles as well as tertiary (gelatinase) granules with, respectively, up-regulation of the membrane expression of the beta2 integrin CD11b, the complement receptor 1 (CD35), and the matrix metalloproteinase-9 (MMP-9). Using the low-affinity formyl peptide receptor-like 1 (FPRL1) antagonist Trp-Arg-Trp-Trp-Trp-Trp (WRW4) and the exchange protein directly activated by cAMP (EPAC)-specific compound 8CPT-2Me-cAMP and measuring the expression of Rap1 GTPase-activating protein as an indicator of EPAC activation, we found that the proinflammatory effect of VIP is mediated via the specific G protein-coupled receptor VIP/pituitary adenylate cyclase-activating protein (VPAC1) receptor as well as via FPRL1: VIP/VPAC1 interaction is associated with a cAMP increase and activation of a cAMP/p38 MAPK pathway, which regulates MMP-9, CD35, and CD11b exocytosis, and a cAMP/EPAC/PI-3K/ERK pathway, which regulates CD11b expression; VIP/FPRL1 interaction results in cAMP-independent PI-3K/ERK activation with downstream integrin up-regulation. In FPRL1-transfected Chinese hamster ovary-K1 cells lacking VPAC1, VIP exposure also resulted in PI-3K/ERK activation. Thus, the proinflammatory effects of VIP lie behind different receptor interactions and multiple signaling pathways, including cAMP/protein kinase A, cAMP/EPAC-dependent pathways, as well as a cAMP-independent pathway, which differentially regulates p38 and ERK MAPK and exocytosis of secretory vesicles and granules.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18174366     DOI: 10.1189/jlb.0507327

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  19 in total

1.  Identification of the early VIP-regulated transcriptome and its associated, interactome in resting and activated murine CD4 T cells.

Authors:  Sheri Tinnell Dorsam; Emilie Vomhof-Dekrey; Rebecca J Hermann; Jodie S Haring; Travis Van der Steen; Erich Wilkerson; Goran Boskovic; James Denvir; Yulia Dementieva; Donald Primerano; Glenn Paul Dorsam
Journal:  Mol Immunol       Date:  2010-02-01       Impact factor: 4.407

Review 2.  Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.

Authors:  William G Robichaux; Xiaodong Cheng
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

3.  Vasoactive intestinal peptide signaling axis in human leukemia.

Authors:  Glenn Paul Dorsam; Keith Benton; Jarrett Failing; Sandeep Batra
Journal:  World J Biol Chem       Date:  2011-06-26

4.  VPAC1 overexpression is associated with poor differentiation in colon cancer.

Authors:  Shaohua Liu; Yunjie Zeng; Yunhua Li; Wenying Guo; Jiali Liu; Nengtai Ouyang
Journal:  Tumour Biol       Date:  2014-03-28

Review 5.  VIP modulates the ALX/FPR2 receptor axis toward inflammation resolution in a mouse model of bacterial keratitis.

Authors:  Thomas W Carion; David Kracht; Eliisa Strand; Edwin David; Cody McWhirter; Abdul Shukkur Ebrahim; Elizabeth A Berger
Journal:  Prostaglandins Other Lipid Mediat       Date:  2018-12-04       Impact factor: 3.072

6.  Cyclic AMP-dependent protein kinase A and EPAC mediate VIP and secretin stimulation of PAK4 and activation of Na+,K+-ATPase in pancreatic acinar cells.

Authors:  Irene Ramos-Alvarez; Lingaku Lee; R T Jensen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-12-06       Impact factor: 4.052

7.  VIP modulates human macrophages phenotype via FPRL1 via activation of RhoA-GTPase and PLC pathways.

Authors:  Zeina Harhous; Wissam H Faour; Nabil El Zein
Journal:  Inflamm Res       Date:  2021-01-27       Impact factor: 4.575

Review 8.  Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease.

Authors:  S G R Smalley; P A Barrow; N Foster
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

Review 9.  Distinct signaling cascades elicited by different formyl peptide receptor 2 (FPR2) agonists.

Authors:  Fabio Cattaneo; Melania Parisi; Rosario Ammendola
Journal:  Int J Mol Sci       Date:  2013-04-02       Impact factor: 5.923

10.  VIPhyb, an antagonist of vasoactive intestinal peptide receptor, enhances cellular antiviral immunity in murine cytomegalovirus infected mice.

Authors:  Jian-Ming Li; Kasia A Darlak; Lauren Southerland; Mohammad S Hossain; David L Jaye; Cassandra D Josephson; Hilary Rosenthal; Edmund K Waller
Journal:  PLoS One       Date:  2013-05-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.